Cargando…

Animal models of multiple sclerosis—Potentials and limitations

Experimental autoimmune encephalomyelitis (EAE) is still the most widely accepted animal model of multiple sclerosis (MS). Different types of EAE have been developed in order to investigate pathogenetic, clinical and therapeutic aspects of the heterogenic human disease. Generally, investigations in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mix, Eilhard, Meyer-Rienecker, Hans, Hartung, Hans-Peter, Zettl, Uwe K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117060/ https://www.ncbi.nlm.nih.gov/pubmed/20558237 http://dx.doi.org/10.1016/j.pneurobio.2010.06.005

Ejemplares similares

Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
por: Monschein, Tobias, et al.
Publicado: (2021)

Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2011)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
por: Neuhaus, Oliver, et al.
Publicado: (2021)

Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
por: Gold, Ralf, et al.
Publicado: (2021)

Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients—A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness
por: Ehler, Johannes, et al.
Publicado: (2017)

The pathophysiology of motor fatigue and fatigability in multiple sclerosis
por: Patejdl, Robert, et al.
Publicado: (2022)

Headaches in Multiple Sclerosis Patients Might Imply an Inflammatorial Process
por: Möhrke, Jan, et al.
Publicado: (2013)

The Cerebrospinal Fluid in Multiple Sclerosis
por: Deisenhammer, Florian, et al.
Publicado: (2019)

New immunopathologic insights into multiple sclerosis
por: Hemmer, Bernhard, et al.
Publicado: (2003)

Editorial: Multiple Sclerosis – From Bench to Bedside: Currents Insights Into Pathophysiological Concepts and Their Potential Impact on Patients
por: Rommer, Paulus S., et al.
Publicado: (2020)

Vaccination and immunotherapies in neuroimmunological diseases
por: Winkelmann, Alexander, et al.
Publicado: (2022)

Headache in the first manifestation of Multiple Sclerosis – Prospective, multicenter study
por: Gebhardt, Marcel, et al.
Publicado: (2017)

Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 1: Empfehlungen
por: Monschein, Tobias, et al.
Publicado: (2021)

Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 2: Impfstofftechnologien
por: Monschein, Tobias, et al.
Publicado: (2021)

Repeated Intrathecal Triamcinolone Acetonide Administration in Progressive Multiple Sclerosis: A Review
por: Abu-Mugheisib, Mazen, et al.
Publicado: (2011)

Polypharmacy in patients with multiple sclerosis: a gender-specific analysis
por: Frahm, Niklas, et al.
Publicado: (2019)

Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications
por: Zanghì, Aurora, et al.
Publicado: (2022)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Animal Models of Multiple Sclerosis
por: Young, Colin R., et al.
Publicado: (2008)

Systematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis
por: Bühring, Jan, et al.
Publicado: (2021)

Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study
por: Frahm, Niklas, et al.
Publicado: (2019)

Clinical trials in multiple sclerosis: potential future trial designs
por: Manouchehri, Navid, et al.
Publicado: (2019)

Epileptic seizures at multiple sclerosis onset and their role in disease progression
por: Grothe, Matthias, et al.
Publicado: (2023)

Coping behavior in multiple sclerosis—complementary and alternative medicine: A cross‐sectional study
por: Rommer, Paulus S, et al.
Publicado: (2018)

Optimizing a Rodent Model of Parkinson's Disease for Exploring the Effects and Mechanisms of Deep Brain Stimulation
por: Nowak, Karl, et al.
Publicado: (2011)

Animal models of Multiple Sclerosis
por: Procaccini, Claudio, et al.
Publicado: (2015)

Animal models of systemic sclerosis: their utility and limitations
por: Artlett, Carol M
Publicado: (2014)

Vaccination in Multiple Sclerosis: Friend or Foe?
por: Zrzavy, Tobias, et al.
Publicado: (2019)

The Molecular Basis for Remyelination Failure in Multiple Sclerosis
por: Gruchot, Joel, et al.
Publicado: (2019)

Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study
por: Winkelmann, Alexander, et al.
Publicado: (2023)

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
por: Thamilarasan, Madhan, et al.
Publicado: (2013)

Risk evaluation and monitoring in multiple sclerosis therapeutics
por: Clanet, Michel C, et al.
Publicado: (2014)

A proinflammatory role for Fas in joints of mice with collagen-induced arthritis
por: Tu-Rapp, Hoang, et al.
Publicado: (2004)

Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents
por: Korsen, Melanie, et al.
Publicado: (2022)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients
por: Hecker, Michael, et al.
Publicado: (2013)

Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany
por: Henze, Thomas, et al.
Publicado: (2014)

Thinking outside the box: non-canonical targets in multiple sclerosis
por: Bierhansl, Laura, et al.
Publicado: (2022)

Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors
por: Frahm, Niklas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9ipc8toha8hkeuedhm9b4b5it0